Abstract

Lysosomal membrane permeabilization caused either via phagocytosis of particulates or the uptake of protein aggregates can trigger the activation of NLRP3 inflammasome- an intense inflammatory response that drives the release of the pro-inflammatory cytokine IL-1β by regulating the activity of CASPASE 1. The maintenance of lysosomal homeostasis and lysosomal membrane integrity is facilitated by the AAA+ ATPase, VCP/p97 (VCP). However, the relationship between VCP and NLRP3 inflammasome activity remains unexplored. Here, we demonstrate that the VCP inhibitors, DBeQ and ML240 elicit the activation of NLRP3 inflammasome in bone marrow-derived macrophages (BMDMs) when used as activation stimuli. Moreover, genetic inhibition of VCP or VCP chemical inhibition enhances lysosomal membrane damage and augments LLoME-associated NLRP3 inflammasome activation in BMDMs. Similarly, VCP inactivation also augments NLRP3 inflammasome activation mediated by aggregated alpha-synuclein fibrils and lysosomal damage. These data suggest that VCP is a participant in the complex regulation of NLRP3 inflammasome activation.

Original languageEnglish
Pages (from-to)1868-1883
Number of pages16
JournalInflammation
Volume47
Issue number5
DOIs
StatePublished - Oct 2024

Keywords

  • ASC speck
  • Alpha-synuclein fibrils
  • Bone marrow-derived macrophages
  • LLoMe
  • NLRP3 inflammasome
  • TAT-Cre recombinase
  • VCP/p97

Fingerprint

Dive into the research topics of 'VCP Inhibition Augments NLRP3 Inflammasome Activation'. Together they form a unique fingerprint.

Cite this